

# Dissecting the mechanisms by which intestinal AIEC promote macrophage-induced inflammation during Crohn's disease







## Internship supervisor: Dr. Laure YATIME


Host Lab: Laboratory of Pathogens and Host Immunity (LPHI)



## **SCIENTIFIC CONTEXT**

Crohn's Disease (CD), a raising inflammatory pathology with no curative treatment

Crohn's disease (CD) is one of the 2 major forms of inflammatory bowel diseases. It is a highly invalidating pathology, characterized by recurrent and very painful inflammatory episodes, associated with numerous extraintestinal complications and an increased risk of colon cancer. The inflammatory burden is fed by an aberrant production of TNFa, elicited by the prevalence of pathogenic species due to intestinal dysbiosis.



No curative treatment exists yet for CD, only palliative treatment with anti-TNFa antibodies.


The constantly raising incidence of the disease urges for the development of **novel anti-CD** therapeutics.

Pathogenic gut microbiota: a promising drug target in CD

## PROPOSED METHODOLOGIES


In vitro approaches - Interactomics and 3D-modelling

1. Identify IbeA's binding partners




*In silico* approaches Virtual pull-down

2. Elucidate IbeA's structure-function relationship




Aim: define IbeA's precise biological function and the redox mechanisms it controls

## Adherent Invasive E. coli (AIEC), a major pathogenic agent in Crohn's Disease (CD)



## In vivo approaches - zebrafish, imaging & transcriptomics


1. Role of IbeA/partners in intramacrophage survival & inflammatory burst



## **OBJECTIVES & PRELIMINARY RESULTS**

#### Identify novel AIEC virulence factors for drug targeting


- O1. Identify VFs important for intramacrophage survival
- O2. Unravel the biological processes they control to induce inflammation



described as required for

invasion, survival & replication

inside macrophages.



Involved in resistance to oxidative stress? Through which mechanims/pathways?

### MORE ABOUT THE PROJECT & TEAM

**Growth assay** 

#### The team: Mechanisms of Normal & Pathological Inflammation





https://lphi.umontpellier.fr/research-teams/mechanisms-of-normal-and-pathological-inflammation/

#### **Recent publications**

WT or \( \Delta \) lbeA

Demou M & Yatime L (2025) bioRxiv 2025.07.25.666771; doi:10.1101/2025.07.25.666771 Hernandez L et al (2025) bioRxiv 2025.06.10.658860. doi:10.1101/2025.06.10.658860 Paris T et al (2024) **FEBS J** 291, 177-203. doi:10.1111/febs.16969 Leiba J et al (2023) **Biology** 12, 153. doi:10.3390/biology12020153

Kowalewski J et al (2021) **PLoS ONE** 16, e0254533. doi:10.1371/journal.pone.0254533

Videos about what we do in our team

https://www.youtube.com/watch?v=azDtPVfmYkA https://www.youtube.com/watch?v=M\_8CuYbYpU0 https://www.youtube.com/watch?v=SMBUqwfKQZU



















